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Abstract
Medium 199 (Gibco) is frequently used to elicit fragile X 
expression. We used this medium, with altered component 
concentrations, to determine the effect of these components on 
fragile X frequency in lymphocytes of fragile X patients or carriers, 
on a normal control and on a fragile X-expressing fibroblast line. 
The components whose concentrations were changed were those that 
participate in folate cycle reactions or which are nucleotide 
precursors.
The deletion of glycine and serine, which would affect the 
concentration of single carbon units and thus 5,10-methylene 
tetrahydrofolate production, had no effect on fragile X frequency. 
However, autosomal chromosome breaks significantly increased in a 
male fragile X subject's cells when serine and/or glycine 
concentrations were perturbed. Purine and thymidine concentrations 
were altered to examine the effect on nucleotide formation. Again, 
there was no significant change in fragile X frequency. In cells 
from another fragile X male, autosomal breaks decreased when purine 
or thymidine deficient media was used. However, the mitotic index 
also decreased, and therefore it may be concluded that ENA 
replication and cell division were negatively affected by these 
deletions. Thirdly, vitamin B,2 deficient media were prepared to 
which different metabolic forms of B12 were added to determine their 
indirect influence on the folate cycle (as coenzymes) and thus on 
fragile X expression. None of the resulting fragile X frequencies 
were significantly different from appropriate complete controls. 
Finally, acridine orange was added to the fibroblast cultures to 
determine its effect on fragile X frequency and the suitability for 
use in diagnosis. These cells had either a lew mitotic index or were 
unscorable due to "stickiness".
THE EFFECT OF TISSUE CULTURE MEDIUM COMPOSITION 
ON FRAGILE X EXPRESSION
INTRODUCTION
The fragile X syndrome, also referred to as the marker X 
syndrome, X-linked mental retardation with macro-orchidism, and the 
Mart in-Bell syndrome, is one of many hereditary forms of mental 
retardation. This syndrome is generally typified by the presence 
of X chromosome breakage under certain tissue culture conditions. 
Persons with this syndrome usually exhibit mild to severe mental 
retardation and certain physical characteristics. The fragile X 
syndrome is thought to be second only to Down's syndrome in 
prevalence, with a frequency estimated from 4 x 10'5 to 5 x 10'4 
among the general population (Turner and Turner, 1974).
Although Lubs first discovered the break in the X chromosome 
in 1969, it was not until the mid-1970's that the associated 
physical findings were described by Turner et al. (1975) and this 
chromosomal defect was recognized as a frequent finding in the 
retarded population. Recognition of this relationship was delayed 
because expression of the break at Xq27, a distal band on the long 
arm of the X chromosame, only occurs in certain tissue culture 
media (Sutherland, 1977).
Since then, the fragile X has been found in virtually all
2
3races and ethnic groups (Blomquist et al., 1982; Herbst and 
Miller, 1980, Howard-Peebles and Stoddard, 1980; Howard-Peebles et 
al., 1979; Gardner et al., 1983; Kaiser-McCaw et al., 1980; Jacobs 
et al., 1980; Mattei et al., 1981; Rhoads et al., 1982; and Turner 
et al., 1978), and a distinctive phenotype has been recognized 
which, for post-pubertal males, may include macro-orchidism, an 
elongated facies, a prominent forehead and chin, large ears, a 
large head circumference, a high arched palate, a jocular 
repetitive speech pattern, and occasionally autistic-like 
tendencies (Brown et al., 1982; de Arce and Kearns, 1984; Herbst 
et al., 1981; Jacobs et al., 1980; Levitus et al., 1983; Schmidt, 
1982; and Tariverdian and Week, 1982). The mental retardation of 
affected males may range from mild to severe. The frequency of 
fragile X expression in males usually does not vary greatly with 
intelligence or age. However, Chudley et al. (1983) and Sherman 
et al. (1984) have observed a small but significant negative age 
effect on fragile X frequency in males.
The fragile X syndrome usually follows a typical x-1 inked 
pattern of inheritance, although some cases of transmission by non­
penetrant males have been reported. In these instances, a male of 
normal intelligence has an affected grandson, borne by the normal 
male's daughter. Apparently, the daughter of the normal male acts 
as carrier for the trait (Gardner, 1984, Nielson et al., 1981; 
Rhoads et al., 1982; Van Roy et al., 1983; and Wolff et al., 1978).
In general, carrier females score dull to normal on IQ tests 
and display the fragile site at low frequencies. Studies indicate
4that fragile X expression in carrier females is inversely 
correlated with IQ and also that it decreases with age (Chudley et 
al., 1983; and Sutherland, 1979b). It has been postulated that the 
variability in IQ correlates with the pattern of X inactivation. 
In accord with the Lyon hypothesis, the abnormal (fragile) X 
chramosame is more frequently the functional X chromosome in 
mentally retarded females, but not in intellectually normal 
heterozygotes (Howard-Peebles, 1983b; Knoll et al., 1984; Paul et 
al., 1984; and Uchida and Joyce, 1982). No characteristic 
phenotype exists for most carrier females, although high arched 
palates, prominent lower mandibles and foreheads, and large ears 
have been noted in some carriers (de Arce and Kearns, 1984; Howell 
and McDermott, 1982; and Taraverdian and Week, 1982).
At present, the fragile X has been demonstrated in 
lymphocytes, fibroblasts, bone marrow cells, lymphoblasts, somatic 
cell hybrids, and, in fetal blood and cultured amniocytes (Byrant 
et al., 1983; Cantu and Jacobs, 1982; Del Pozo and Millard, 1983; 
Fonatsch et al., 1981; Gardner et al., 1982; Hecht et al.. 1982; 
Jacobs et al., 1982; Jenkins et al., 1981; Nussbaum et al., 1983; 
Shapiro et al., 1982; Simola, 1982; Steinbach et al., 1983; and 
Webb et al., 1981). No culture condition exists which will elicit 
100% fragile X expression in either affected males or carrier 
females. The normal range of expression varies from 3 - 68% 
(Howard-Peebles and Pyror, 1981; and Turner, 1982) and is usually 
much higher in hemizygous males than in carrier females. 
Frequently, obligate females do not demonstrate the fragile X
5(Hecht et al., 1982; Howard-Peebles and Pyror, 1981; and 
Taravendian and Week, 1982). There exists a need for the 
development of a definative diagnostic test, especially for use in 
prenatal diagnosis (Brookwell et al., 1982; and Sutherland and 
Jacky, 1982).
Although the etiology of the syndrome has yet to be 
determined, the expression of fragility is linked to perturbations 
of folic acid metabolism. It is known that inborn errors in folate 
metabolism often cause mental retardation, and Lejeune (1982) has 
reported that oral folic acid administration has resulted in 
improved motor coordination and developmental progress in an 18 
month-old patient. Also, in vitro treatments which augment folate 
metabolism usually decrease fragile X frequency and vice versa. 
Thus, culture media deficient in folate compounds and thymidine, 
or containing methotrexate (MIX), a dihydrofolate reductase 
inhibitor (see Reaction 5, Figure 1), or flurodeoxyuridine (RJdR), 
an inhibitor of thymidine synthetase (TS) (see Reaction 1, Figure
1) have been reported to markedly enhance the in vitro expression 
of the fragile site (McBumey and Whitmore, 1975; Sutherland, 1983; 
Sutherland, 1979a; Glover, 1981; Tommerup et al., 1981; and
Brookwell et al., 1982), while the addition of folic acid, folinic 
acid, thymidine, or 5-bromo-2' -deoxyuridine (BCJdR) to folate- 
deficient media has been found to inhibit fragile X expression 
(Glover, 1981; Martin et al., 1980; and Sutherland, 1979a). Medium 
TC199, a low folate medium, is used most often in the diagnosis of 
the syndrome.
6The folate cycle functions to provide single carbon units for 
various cellular anabolic processes. Tetrahydrofolate is the basic 
compound utilized for these carbon-carrying roles (Krumdieck et 
al.. 1983; and Stryer, 1981). The different carbon units carried 
by tetrahydrofolate are:
1) methyl (-CH3)
2) methylene (-CH2)
3) methenyl (-CH)
4) formyl (-CHO)
5) formimino (-CH=NH)
6) hydroxy-methyl (-CH2OH)
Mammals cannot synthesize folic acid, the precursor of 
tetrahydrofolate, and thus must acquire it through their diet. 
Then, through two enzymatic reactions, folate is converted to 
tetrahydrofolate which will then react with a carbon donor, either 
serine, glycine, or formaldehyde, to form 5,10-methylene 
tetrahydrofolate (see Reaction 2, Figure 1). Glycine is also a 
product when the carbon donor is serine. These two amino acids are 
the main carbon-donating compounds (Blair, 1975; and Lehninger, 
1982).
5.10-Methylene tetrahydrofolate may then undergo further 
modifications, to yield any of the previously listed carbon- 
carrying tetrahydrofolates. These carbon units are then utilized 
in anabolic reactions (Benkovic and Lazarus, 1984).
5.10-Methylene tetrahydrofolate may be reduced to 5-methyl 
tetrahydrofolate. 5-Methyl tetrahydrofolate can be recycled
7through the transfer of the methyl group to homocysteine, forming 
methionine (Sauer and Wilmanns, 1977; and Scott and Weir, 1981) 
(see Reaction 3, Figure 1). Tetrahydrofolate is the other product. 
If 5-methyl tetrahydrofolate is not reconverted to 
tetrahydrofolate, the 5-methyl tetrahydrofolate pool in the cell 
will enlarge and thereby produce a deficit in the availability of 
other folates for use in metabolic processes (Herbert and Das, 
1976; and Perry et al., 1979).
Hypothetically, the expression of X chromosome fragility in 
the fragile X syndrome could result from an alteration in the 
structure or function of DMA and/or chromosomal proteins. Most 
current hypotheses focus on malfunctions or deficiencies in the 
formation of nucleotides or their precursors, or on perturbations 
of the ratios of nucleotides. Two principle deficiencies that 
could occur are an inadequate deoxythymidinemonophosphate (dTMP) 
pool and an inadequate purine pool. Either or both of these could 
result from inadequate availability of carbon-carrying 
tetrahydrofolates or other coenzymes. In addition, perturbations 
of the folate cycle could result in a deficiency of S- 
adenosylmethionine (SAM) Which is used in ENA methylation. Also, 
if there were to be a shortage of single carbon units available for 
transfer to tetrahydrofolate (THF), e.g. serine and/or glycine, the 
carbon-carrying tetrahydrofolates would also disrupt the folate 
cycle and lead to increased X fragility and breakage in autosomal 
chromosomes. If this were the case, the addition of these amino 
acids should decrease fragile X expression.
8The most widely accepted hypothesis proposes that disruption 
of the folate cycle interferes with the formation of proper levels 
of deoxythymidinemonophosphate which, in turn, leads to fragile X 
expression and autosomal chromosome breakage. It has been 
suggested repeatedly that fragile X expression results from 
inadequate activity of TS, the enzyme responsible for the 
conversion of 21 -deoxyuridine-5' -phosphate (dUMP) to 2 '- 
deoxythymidine-5' -phosphate (dTMP) (see Reaction 1, Figure 1) 
(Brookwell et al., 1982; and Howard-Peebles, 1983b). 5,10-
Methylene tetrahydrofolate is a coenzyme for this reaction, binding 
to TS to form the functional holoenzyme. Experiments involving 
fluorodeoxyuridine (RJdR) appear to support this hypothesis (Glover 
and Howard-Peebles, 1983; and Kalman and Yalowich, 1979). When 
RJdR is added to culture media, fragile X frequency increases. The 
mode of action of RJdR is to bind to TS, thereby inhibiting it. 
However, this effect can be overcome by the addition of thymidine, 
which decreases the fragile X frequency (Gardiner et al., 1984). 
Therefore, it seems that a deficiency occurs in the activity of the 
enzyme (Glover, 1981; and Tommerup et al., 1981).
Until recently, the possibility existed that this evidence may 
have been misinterpreted. Erbe (1979) assayed the in vitro 
activities of thymidylate synthetase and other enzymes involved in 
folate metabolism and found their activities to be normal in 
fragile X males. RJdR binds to the holoenzyme, not just the 
apoenzyme, as has been assumed by most researchers (Lockshin et 
al.. 1984; and Reyes and Heidelberger, 1965). Thus, experimental
9evidence did not exclude the possibilty that the relevant effect 
of RJdR is the removal of 5,10-methylene tetrahydrofolate from the 
folate pool resulting in inhibition of normal folate recycling. 
This interpretation now appears unlikely. In hybrids between TS 
negative Chinese hamster and fragile X cells, fragile X expression 
can be induced at high frequency by limiting the supply of 
exogenous thymidine, or by providing abnormally high thymidine 
levels, irrespective of folate concentration. Fragile X expression 
is absent in the presence of moderate concentrations of exogenous 
thymidine (Nussbaum et al., 1986).
The other hypothesis directly related to ENA synthesis 
involves the purine pool. Both the conversion of 51 -
phosphoribosylglycineamide to 5' -phosphoribosyl- formylglycineamide 
(see Reaction 6, Figure 1), and the conversion of 51 -phophoribosyl- 
5-aminoamidazole-4-carboxamide to 51-phosphoribosyl-5- 
formamidoimidazole-4-carboxamide (see Reaction 4, Figure 1) require 
coenzymes. 10-Formyltetrahydrofolate, the coenzyme used in 
Reaction 4, is formed by the catalytic addition of a formate group 
to THF (see Reaction 9, Figure 1). In Reaction 6, 5,10-methylidyne 
tetrahydrofolate is produced by the spontaneous loss of a water 
molecule and the enzymatically-catalyzed loss of a hydrogen ion 
from THF (see Reactions 7 and 8). If the disruption lies in the 
formation of folates or their function as coenzymes in the above 
two reactions, a decrease in DNA synthesis could occur. If one or 
both of these tetrahydrofolate coenzymes were present at inadequate 
levels, then the addition of the ultimate products, i.e., guanine
10
and adenine, to the media should decrease fragile X frequency and 
also autosomal chromosome breakage. If the primary defect does not 
involve purine synthesis, then the addition of these nucleic acid 
precursors should not have major effects on fragile X frequencies.
The third hypothesis focuses on the possible involvement of 
post-synthesis ENA methylation on the induction of fragile X 
expression. Methionine, a precursor of SAM, the methyl donor for 
such methylations, increases fragile X frequency (Howard-Peebles 
and Pyror, 1981). 5-Azacytidine (an inhibitor of ENA methylation) 
and S-adenosylhamocysteine (an inhibitor of the synthesis of SAM) 
reverse the effect of methionine (Sauer and Wilmanns, 1977; and 
Mixon and Dev, 1983). Unfortunately, this latter study was done 
with inadequate controls and the results cannot be considered 
definitive.
At present, the most likely relatively proximal cause of in 
vitro fragile X egression is dTMP depletion, which may result from 
a more distal disturbance of folate metabolism. Any metabolic 
block of the folate cycle would effectively result in the 
linearization of the cycle from its start to the point of the 
block. Derivatives of folic acid would then no longer behave as 
coenzymes but rather as reactants, since recycling would be 
impaired (Hagerman et al., 1983; and Marquet et al., 1981).
The homocysteine to methionine conversion (Reaction 3, Figure 
1) would be a perfect site for such a linearization, and some 
observations suggest that this conversion might be involved. 
Lejeune (1981) showed that methionine increases and homocysteine
11
decreases fragile X egression. It is therefore unlikely that this 
reaction is completely blocked. A partial block, perhaps resulting 
from limited availability of irethylcobalamin (an active form of 
Vitamin B12) would be consistent with most accepted data. Vitamin 
B12 is usually assimilated as cyanocbbalamin or hydroxycobalamin and 
then converted to both methylcobalamin and adenosylcobalamin 
(Herbert and Das, 1976). The adenosylcobalamin is used as a 
ooenzyme in the conversion of methylmalonyl CoA to succinyl CoA, 
which is then utilized in the TCA cycle (Lehninger, 1982; and 
Herbert and Das, 1976). Hoegerman (personal communication, 1984) 
examined a male patient with methylmalonylaciduria (an hereditary 
defect of B12 metabolism) who had the typical ears and macro­
orchidism of the fragile X syndrome, but who was fragile X 
negative. A defect in the conversion of cyanocobalamin to both 
methylcobalamin and adenosylcobalamin might account for these 
features. Therefore, it appeared plausible that there may be a 
defect in the fragile X syndrome in which adenosylcobalamin is 
formed but neither cyanocobalamin nor adenosylcobalamin is 
converted to methylcobalamin in adequate amounts (Hoegerman, 
personal communication, 1984).
In summary, in vitro deficiencies in compounds other than 
folate reactants, e.g., coenzymes of the folate cycle, should be 
considered as causative factors in the production of the fragile 
X syndrome (Metz et al., 1968). In vitro, inadequate thymidylate 
synthesis and a decrease in the dlMP pool appear highly probable, 
but the involvement, if any, of events preceding thymidylate
12
synthesis and the mechanism leading from a decreased cTIMP pool to 
the expression of fragility are unknown. Figures 2 and 3 summarize 
the incomplete nature of our present knowledge. It is also unknown 
whether mental retardation is a relatively direct consequence of 
metabolic disturbance resulting from the presence of an abnormal 
allele at the locus of fragility or an indirect consequence of the 
fragility. In this latter alternative, in vivo fragility would 
result in nulloscmy for loci distal to the breakpoint.
Of the hypotheses discussed above, this study tested the 
involvement of carbon donors in folate cycle metabolism, the 
disruption of DNA synthesis due to dlMP or purine pool depletion, 
and the effect of variability in Vitamin B12 coenzyme availability 
in an attempt to identify reactions involved in the in vitro 
generation of fragile X expression. The development of a more 
effective means of carrier detection and/or prenatal diagnosis 
through the use of experimentation with clastogens and/or general 
metabolic poisons was also a goal.
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Fig. 2. A mcxiel for the fragile X syndrome in vitro.
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Fig. 3. A model for the fragile X syndrome in vivo.
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METHODS AND MATERIALS
Presently, the most commonly used nutrient mixture for fragile 
X detection is TC 199. In addition to NaHCX^ , the following 
components, all of which, may theoretically affect folate metabolism 
and/or DMA synthesis, were deleted from TC 199 to produce a lOx 
custom-compounded medium (GIBCO Formula 84-0072) which was the basis 
for experimentation. (The formulation of regular TC 199 is given in 
Appendix 1.)
1) glycine
2) hypoxanthine
3) adenylic acid
4) adenine sulfate
5) thymine
6) L-cysteine
7) folic acid
8) Ir-glutamine
9) guanine hydrochloride
10) xanthine
11) L-cystine
12) pyridoxine hydrochloride
13) ATP
14) DL-methionine
15) ascorbic acid
16) DIr-serine
17) pyridoxal HC1
The readdition of seme, but not all, of these compounds to 
medium compounded from the custom medium would allow determination
16
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of the effects of the absence of the components which remain deleted.
Howard-Peebles (1981), for example, has shewn that the addition 
of methionine to complete medium will increase fragile X frequency. 
By adding back all of the deleted compounds except methionine, it 
could be determined whether the absence of methionine would decrease 
fragile X expression.
Fragile X culture medium consisted of 10 ml of custom-compounded 
lOx TC 199 and 90 ml double-distilled water supplemented with:
5.25 ml Fetal Bovine Serum (FBS) (Gibco)
1.00 ml PSN antibiotic (Gibco)
2.00 ml 1M Hepes buffer (Gibco)
2.00 ml phytohaemaglutinin (EHA) (Wellcome)
(added to media used for lymphocyte culture 
only)
Finally, the complete fragile X medium was adjusted to pH 7.6 
with IN NaOH. Blood samples from known fragile X patients and a 
fibroblast line derived from a fragile X patient were tested in 
custom-compounded fragile X media.
Peripheral venous blood samples of 10-20 ml were collected in 
heparinized vacutainers. Lymphocyte cultures, consisting of a 0.4 
ml inoculum in 5 ml of custom-compounded fragile X medium, were 
established on the day of specimen procurement. The plasma inoculum 
contained leucocytes and a small amount of erthrocytes.
Cultures were incubated in 30 ml flasks (Nunc) at 37°C for 86 hr. 
Cultures were then transferred to centrifuge tubes, the pH readjusted 
to 7.6 with IN NaOH and incubated for an additional 6 hr. Two hr 
prior to harvesting, colcemid (2ug) was added to each culture.
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Cultures were harvested by conventional techniques, using 0.075 
M KC1 for 10 min as the hypotonic treatment, and 3 methanol: 1 
glacial acetic acid (v:v) as the fixative. An initial 20 min 
fixation period was followed by further washes in fixative until the 
pellet, following centrifugation, appeared white.
The fixed cells, suspended in fixative, were then dropped from 
a Pasteur pipette onto wet slides, dried, and stained with Giemsa 
(Fisher) for 5 min. When possible, one hundred intact metaphases per 
treatment were scored for X and autosomal chromosome breaks at 1250x 
using a Zeiss Photomicroscope II. After tentative identification and 
photography of fragile X chromosomes, slides were destained using the 
series:
1) xylene
2) xylene
3) xylene
4) 50:50 xylene:absolute ethanol
5) absolute ethanol
6) absolute ethanol
Each bath lasted 5 min. Slides were then restained using 
quinacrine mustard and citric acid sodium phophate buffer (pH 5.5) 
to produce Q-banding, and coverslipped. Using a Zeiss Fluorescent 
Fhotomicroscxpe, fragile X chromosomes were pxositively identified and 
photographed.
Fibroblasts were maintained in 75 cm2 flasks (Costar), with 
Nutrient Mixture F10, supplemented with 20% FBS, glutamine, and 
antibiotic and grown in an atmosphere of 5% C02. Cells were fed
19
weekly. Forty-eight hr prior to the initiation of an experiment, 
cells, from confluent flasks, were passaged (1:6 split) in the above 
medium. After 48 hr, the passage medium was replaced with custom- 
ccmpounded fragile X medium (20 ml per flask). Cultures were then 
grown for an additional 48 hr. Six hr prior to fixation, colcemid 
(4 ug) was added. Immediately preceding fixation, cells were 
trypsinized with EDTA trypsin (Gibco). The cells and media were 
transferred to centrifuge tubes and harvested as previously described 
for lymphocytes.
The experiments, described below, center on folate metabolism 
and diagnostic techniques.
1) All deleted components, except serine and glycine, were added 
back to their normal concentrations. Serine and glycine, both alone 
and in combination, were replaced to concentrations equal to 0, 25, 
and 50% of normal. The function of this test was to determine the 
effect of the availability of single carbon units on fragile X 
frequency in lymphocytes and fibroblasts.
2) All deleted components, except either the purines and purine 
precursors (media components 2, 3, 4, 9, 10) or thymine, or neither, 
were added back to their normal concentrations in order to study the 
effect of ENA precursors on fragile X frequency in lymphocytes and 
fibroblasts.
3) Adenosylccbalamin, hydroxycobalamin, and methylcbbalamin were 
added to standard commercial medium TC 199 at 10 and 20 times the 
concentration of 1.36 mg/1 to determine the effect of vitamin B12 and 
its coenzyme and dietary forms on lymphocyte fragile X frequencies.
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(Medium TC 199 is normally deficient in B12's while medium F10, in 
which X fragility is absent, contains B12 at a concentration of 1.36 
mg/1).
4) Acridine orange, a known clastogen (Hsu et al., 1977), was 
added to different fibroblast cultures in concentrations of 2.0 uM 
and 20.0 UM, at 2, 5, and 48 hr prior to harvest to determine its 
effect on fragile X frequency.
5) A positive control, using a combination of 0.1 itiM FUdR added 
24 hr prior to harvest and 2.2 mM caffeine added 6 hr prior to 
harvest, was performed to confirm the capacity of the fibroblast line 
to express fragile X and for comparison with acridine orange induced 
fragility (Yunis and Soreng, 1984).
The acridine orange experiments and the positive control were 
run using medium made with complete TC 199.
Blood samples used in this study were excess clinical samples, 
drawn with parental consent, from fragile X patients at Eastern 
Virginia Medical School. K.D., P.W., and L.A.D. are all mentally 
retarded, fragile X positive males with same of the physical 
characteristics of the syndrome. L.D., a female, is known to be a 
carrier only from pedigree data. She has an affected son and an 
intellectually normal daughter. X fragility has been cytogenetically 
demonstrated in both progeny. Her clinical studies yielded negative 
findings.
The fibroblast line, GM4024A, obtained from the NIGMS Human 
Genetic Cell Repository, Camden, NJ, was derived from a fragile X 
male. Treatment with FUdR was reported to result in 4% fragile X
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expression in this fibroblast line.
The donor of the control blood samples, J.H., is a mentally and 
physically normal female.
RESULTS
Experiments involving the deletion of serine and/or glycine from 
TC 199 (Tables 1 and 5) and also of thymine and the purine 
precursors (Tables 2 and 6) revealed no trends or variations in the 
expression of X fragility in the lymphocytes from the fragile X 
patients. However, there were some significant differences in 
autosomal chromosome breakage. In the single carbon unit
availability experiment, the Gibco and custom-complete 199 controls 
differed significantly at a 5% probability level (the data was 
analyzed using a contingency Chi-square test and a 5% probability 
level was used for all experiments) for J.H. and P.W. The 199 - 
serine and 199 + .25X glycine, + .25X serine treatments significantly 
increased autosomal breakage in P.W.'s chromosomes.
The removal of purine precursors also affected autosomal 
chromosome breakage. Breakage decreased significantly in J.H.'s 
chromosomes grown in purine and thymine deficient 199. Similarly, 
chromosomes from L.A.D. grown in 199 without purines or 199 without 
thymidine showed significantly less autosomal breakage. In the 
serine and/or glycine deletion and thymidine and/or purines deletion 
experiments, cells from both the fibroblast line, GM4024A, and the
22
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fragile X carrier, L.D., demonstrated no X fragility. Same 
representative fragile X chromosomes are shown in Figs. 4 and 5. In 
the thymine and purine precursor experiment, the cells from fragile 
X patient, P.W., were scored blindly.
The cobalamin experiment did result in some variations in fragile 
X expression (Table 3). These cells were blindly scored. The 
initial phase of the experiment was conducted with 10X cobalamin 
concentrations. The cells grown with 10X hydroxycobalamin and 
methylcobalamin showed a higher fragile X frequency than the Gibco 
199 control. A subsequent run utilizing 20X concentrations, again 
elicited a higher frequency with methylcobalamin. These differences, 
however, were not significant. The 20X hydroxycobalamin and both 
adenosylcobalamin treatments produced lower, although 
nonsignificantly so, fragile X frequencies. There was a large 
discrepancy between the 199 complete and 199 Gibco controls. The 
Chi-square for the comparison of these two controls was 3.41. This 
discrepancy was repeated (Table 7) in the amount of autosomal 
chromosomal breakage.
Additionally, the only fragile X found in L.D., an obligate 
carrier (mother of L.A.D., a fragile X male), was demonstrated in 
this experiment with the 10X methylcobalamin treatment (Fig. 6). 
This increase in fragile X frequency was not statistically 
significant.
In the final experiment, the FUdR and caffeine treatment did 
result in a slight, although nonsignificant, increase in X fragility. 
FUdR is usually required to induce X fragility in fibroblasts.
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Autosomal gaps and isogaps, as shown in Fig. 7 also increased. The 
acridine orange treatments were unsuccessful due to greatly 
diminished culture growth or the presence of unscorable, "sticky" 
metaphases (Table 4).
The FUdR plus caffeine treatment acted as a positive control to 
ensure that the fibroblast line had retained the ability to express 
X chromosome fragility after many passages.
It should be noted that several of the cultures, as indicated 
in the tables, became bacterially contaminated. This could have 
negatively or positively affected fragile X expression in these 
cultures.
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Fig. 4 A Giemsa-stained, fragile X-containing cell from 
L.A.D. (The fragile X chromosome is indicated by 
an arrow).
f* S
33
Fig. 5. Giemsa-stained chromosomes illustrating the 
variable appearance of the fragile X: a) a 
single break at locus Xq28 b) an isogap c) a 
transposed isogap d) an endoredupl icated 
fragile X. (The fragile X chromosomes are 
indicated by arrows).
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Fig. 6. The fragile X cell found in carrier L.D.: 
a) Giemsa-stained b) Q-banded. (The 
fragile X chromosomes are indicated by 
arrows).

Examples of a) autosomal gaps and isogaps 
and b) tri-radial formation in GM4024A 
fibroblast cells treated with FUdR and 
caffeine. (The triradial is indicated 
by an arrow).
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DISCUSSION AND CONCLUSION
The primary function of this study was to investigate aspects 
of the biochemical interrelationships between folic acid metabolism, 
ENA synthesis, and fragile X expression. From the data obtained, it 
appears that none of the hypothesized reactions are directly related 
to fragile X formation. This conclusion is consistent with recent 
findings which suggest that the relationship of folic acid metabolism 
to fragile X expression is limited to indirect control of the level 
of the thymidylate pool.
It appears that limiting media concentration of serine and 
glycine, which hypothetically could lead to a shortage of single 
carbon units and thus perturb the folate cycle, cannot be used to 
induce breakage at the fragile site at Xq27. None of the 
combinations of glycine and/or serine deletion or reduction produced 
a significant increase in X fragility. However, altering serine and 
glycine concentrations may have affected autosomal replication or ENA 
repair mechanisms in some way, since autosomal breakage increased for 
some treatments. In addition, the largest difference in fragile X 
frequency was between the custom-ccirpounded 199 and Gibco 199 
controls. Although the compositions of both media were theoretically 
identical, a component of the Gibco medium which normally decreases
36
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fragile X expression may have lost activity or, alternatively, a 
component necessary for fragile X expression may have had a lower 
activity in the custom-compounded medium than in the Gibco medium.
It should also be considered that in tables with large numbers 
of comparisons some, by chance, will be significant due to random 
variability. For instance, upon addition of the number of autosomal 
breaks in the J.H. (control) samples for the custom-compounded and 
Gibco 199 treatments from Tables 5,6,and 7, the totals did not differ 
greatly: 30/300 and 24/200, respectively. The above hypothesis was 
also indirectly tested in the experiment in which thymidine and 
purine precursors were deleted from the medium, since the resulting 
increased need for de novo purine synthesis would lead to decreased 
intracellular levels of the carbon carrying folates. Again, there 
was no significant change in the frequency of X fragility. This 
latter experiment also suggests that a folate coenzyme malfunction 
is probably not involved in fragile X formation as carbon-carrying 
folates act as coenzymes in purine formation reactions (reactions 4 
and 6).
In some cases, the deletion of purine and thymidine precursors 
significantly decreased autosomal chromosome breakage. This was 
contrary to expected results and may also have been due to random 
fluctuations. Had a larger sample size been available the difference 
with the control may have decreased. However, the treatments 
obviously had some effect on DMA replication since the standard 
number of dividing cells could not even be scored for the 199 - 
purines treatment. The third experiment, which tested for the
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possible effect of varying the presence and concentration of various 
cobalamin coenzymes on fragile X expression also yielded 
nonsignificant differences between treatments and controls. While 
no treatment significantly affected fragile X expression, the general 
trends in the experiment were very different from those expected. 
Methylcdbalamin was predicted to lower fragile X frequencies, but 
fragile X expression was elevated in both cultures to which different 
concentrations of methylcobalamin had been added, as previously 
mentioned. The only significant difference in this experiment was 
the frequency of autosomal breakage in the Gibco and custom- 
compounded 199 treatments. This may have been due to fluctuations 
in the activity of media components or random variability, as 
previously stated.
FUdR treatment successfully demonstrated that the fragile X 
fibroblast line had retained its ability to express fragile X. Such 
treatment was not successful in inducing fragile X expression in the 
female obligate carrier's lymphocytes. It did however result in a 
high level of non-specific chromosome breakage.
Acridine orange, at the tested concentrations, is not a suitable 
agent for the induction of chromosome breakage. Even at the lowest 
concentrations tested, treated chromosomes were unscorable due to 
stickiness. In addition, the mitotic index was unacceptably low.
In summary, none of the tested alterations of the tissue culture 
medium significantly affected in vitro fragile X expression. 
Currently, it is believed (Nussbaum et al., 1985, Sutherland and 
Baker, 1986), that such egression is dependent on the relative
39
levels of precursor nucleosides and/or nucleotides. If this is 
correct, we can conclude that the tested alterations did not 
significantly affect folic acid metabolism to perturb precursor pools 
and thus, indirectly, fragile X expression.
40
APPENDIX
Medium 199
COMPONENT mg/L
DL-Alanine 50.00
L-Arginine HC1 70.00
DL-Aspartic acid 60.00
L-Cysteine HC1 - HaO 0.11
L-Cystine 20.00
L-Cystine 2HC1 —  —
DL-Glutamic acid - H»0 150.00
L-Glutamine 100.00
Glycine 50.00
L-Hystidine HC1 - HaO 21.88
L-Hydroxyproline 10.00
DL-Isoleucine 40.00
DL-Leucine 120.00
L-Lysine HC1 70. 00
DL-Methionine 30.00
DL-Phenylalanine 50.00
L-Proline 40. 00
DL-Serine 50.00
DL-Threonine 60.00
DL-Tryptophan 20. 00
L-Tyrosine 40.00
L-Tyrosine (disodium salt) - -
DL-Valine 50.00
VITAMINS:
Ascorbic acid 0.05
Alpha tocopherol phosphate
(disodium salt) 0.01
d-Biotin 0.01
Calciferol 0.10
D— Ca pantothenate 0.01
Choline chloride 0.50
Folic acid 0.01
i-Inositol 0 . 05
Menadione 0 .01
Niacin 0.025
Niacinamide 0.025
Para-aminobenzoic acid 0.05
Pyridoxal HC1 0.025
Pyridoxine HCl 0 . 025
Riboflavin 0.01
Thiamine HCl 0.01
Vitamin A (acetate) 0.14
COMPONENT
INORGANIC SALTS: 
CaCla (anhyd.) 
Fe(NOs)a - 9H^O 
KC1
KH P^O-*
MgSO-* (anhyd.) 
MgSCU - 7HitO 
NaCl 
NaHCOa 
NaH=*PO-*
NaaHPO^
Na^HPOa
mg/L
140
0
400
60
200
8000
350,
00
72
00
00
00
00
00
- HaO - -
(anhyd.) - -
- 7HaO 9 0.00 
OTHER COMPONENTS:
Adenine sulfate 10.00
Adenosinetriphosphate 
(Disodium salt) 1
Adenylic acid 0
Cholesterol 0
Deoxyribose 0
D-Glucose 1000
Glutathione (reduced) 0
00
20
20
50
00
05
30
30
Guanine HC1 0
Hypoxanthine 0
Hypoxanthine (Na salt)- -
Phenol red 20.00
Ribose 0.50
Sodium acetate 50.00
Thymine 0.30
Tween 8 0 20.00
Uracil 0.30
Xanthine 0.30
Xanthine (Na salt) - -
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